Atherosclerosis: A complex interplay of inflammatory processes

Future Lipidology

Volumn 4, Issue 2, 2009, Pages 167-187

  Harangi, Mariann ^a   Szodoray, Peter ^a   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Atherosclerosis; Chronic inflammation; Innate and adaptive immunity; Oxidized LDL; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; AUTOANTIGEN; C REACTIVE PROTEIN; CD40 LIGAND; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; RESISTIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CHLAMYDIAL PNEUMONIA; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; HUMORAL IMMUNITY; HYPERCHOLESTEROLEMIA; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; LIPID OXIDATION; LIPID PEROXIDATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

EID: 67249107506     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.1     Document Type: Review

References (167)

1. Dodson PM, Horton RC: The nature of atheroma. Proc. Nutr. Soc. 46(3),331-336 (1987).
2. Benditt EP, Benditt JM: Evidence for a monoclonal origin of human atherosclerotic plaques. Proc. Natl Acad. Sci. USA 70(6), 1753-1756 (1973).
3. Ross R, Glomset J, Harker L: Response to injury and atherogenesis. Am. J. Pathol. 86(3), 675-684 (1977).
4. Ross R, Glomset JA: The pathogenesis of atherosclerosis. N. Engl. Med. 295(7), 369-377 (1976).
5. Ross R: The pathogenesis of atherosclerosis - an update. N. Engl. Med. 314(8), 488-500 (1986).
6. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86(2), 515-581 (2006).
7. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383-1389 (1994).
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. Med. 339, 1349-1357 (1998).
9. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 111(25), 3481-3488 (2005).
10. Geisler T, Bhatt DL: The role of inflammation in atherothrombosis: current and future strategies of medical treatment. Med. Sci. Monit. 10(12), RA308-RA316 (2004).
11. Paoletti R, Gotto AM, Hajjar DP: Inflammation in atherosclerosis and implications for therapy. Circulation 109(23 Suppl. 1), III20-III26 (2004).
12. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 109(21 Suppl. 1), II2-II10 (2004).
13. Licastro F, Candore G, Lio D et al.: Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun. Ageing 2, 8 (2005).
14. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. Med. 352(16), 1685-1695 (2005).
15. Matsuura E, Hughes GR, Khamashta MA: Oxidation of LDL and its clinical implication. Autoimmun. Rev. 7(7),5 58-566 (2008).
16. Mertens A, Holvoet P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 15(12), 2073-2084 (2001).
17. Lankin VZ, Tikhaze AK, Kapel'ko VI et al.: Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative and carbonyl stress. Biochemistry (Mosc). 72 (10),1081-1090 (2007).
18. Watson AD, Leitinger N, Navab M et al.: Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272(21), 13597-13607 (1997).
19. Leitinger N, Tyner TR, Oslund L et al.: Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc. Natl Acad. Sci. USA 96(21), 12010-12015 (1999).
20. Rajavashisth TB, Andalibi A, Territo MC et al.: Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344(6263), 254-257 (1990).
21. Kohno M, Yokokawa K, Yasunari K et al.: Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98(4), 353-359 (1998).
22. 2-terminal protein kinases in atherosclerotic lesions coincide with p53. Am. J. Pathol. 156(6), 1875-1886 (2000).
23. Namgaladze D, Kollas A, Brüne B: Oxidized LDL attenuates apoptosis in monocytic cells by activating ERK signaling. J. Lipid Res. 49(1), 58-65 (2008).
24. Hundal RS, Gomez-Munoz A, Kong JY et al.: Oxidized low density lipoprotein inhibits macrophage apoptosis by blocking ceramide generation, thereby maintaining protein kinase B activation and Bcl-XL levels. J. Biol. Chem. 278(27), 24399-24408 (2003).
25. Hundal RS, Salh BS, Schrader JW, Gomez-Munoz A, Duronio V, Steinbrecher UP: Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI3-kinase/PKB pathway. J. Lipid Res. 42(9), 1483-1491 (2001).
26. 2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin. Dev. Immunol. 10(2-4),203-211 (2003).
27. Shoenfeld Y, Wu R, Dearing LD, Matsuura E: Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 110(17), 2552-2558 (2004).
28. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21(12), 1876-1890 (2001).
29. Swanberg M, Lidman O, Padyukov L et al.: MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat. Genet. 37(5), 486-494 (2005).
30. Nilsson J, Hansson GK: Autoimmunity in atherosclerosis: a protective response losing control? J. Intern. Med. 263(5), 464-478 (2008).
31. Sherer Y, Shoenfeld Y: Atherosclerosis: is atherosclerosis a cellular or humoral mediated auto-immune disease? Ann. Rheum. Dis. 61(2), 97-99 (2002).
32. Binder CJ, Shaw PX, Chang MK et al.: The role of natural antibodies in atherogenesis. J. Lipid Res. 46(7), 1353-1363 (2005).
33. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF; DCCT/ED Research Group: Proatherogenic and proinflammatory properties of immune complexes prepared with purified human Ox-LDL antibodies and human Ox-LDL. Clin. Immunol. 105(1), 81-92 (2002).
34. Ameli S, Hultgårdh-Nilsson A, Regnström J et al.: Effect of immunization with homologous LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16(8), 1074-1079 (1996).
35. Freigang S, Hörkkö S, Miller E, Witztum JL, Palinski W: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18(12), 1972-1982 (1998).
36. Hörkkö S, Bird DA, Miller E et al.: Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103(1), 117-128 (1999).
37. Shaw PX, Hörkkö S, Tsimikas S et al.: Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler. Thromb. Vasc. Biol. 21(8), 1333-1339 (2001).
38. Lehtimäki T, Lehtinen S, Solakivi T et al.: Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 19(1), 23-27 (1999).
39. Erkkilä AT, Närvänen O, Lehto S, Uusitupa MI, Ylä-Herttuala S: Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20(1), 204-209 (2000).
40. Salonen JT, Ylä-Herttuala S, Yamamoto R et al.: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339(8798), 883-887 (1992).
41. Tinahones FJ, Gómez-Zumaquero JM, Garrido-Sánches L et al.: Influence of age, and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J. Lipid Res. 46(3), 452-457 (2004).
42. Balada E, Ordi-Ros J, Matas L, Mauri M, Buján S, Vilardell-Tarrés M: Atherosclerosis and anti-oxidized low density lipoprotein antibodies in an elderly population. Med. Clin. (Barc). 119(5), 161-165 (2002).
43. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF: OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J. Lipid Res. 47(9), 1975-1983 (2006).
44. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF: Antibodies to oxidized LDL predict coronary artery disease in Type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48(7), 1454-1458 (1999).
45. Lopes-Virella MF, Virella G, Orchard TJ et al.: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 90(2), 165-172 (1999).
46. Orekhov AN, Kalenich OS, Tertov VV, Novikov ID: Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue React. 13(5), 233-236 (1991).
47. Costacou T, Lopes-Virella MF, Zgibor JC et al.: Markers of endothelial dysfunction in the prediction of coronary artery disease in Type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J. Diabetes Complicat. 19(4), 183-193 (2005).
48. Virella G, Lopes-Virella MF: Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 200(2), 239-246 (2008).
49. Virella G, Thorpe SR, Alderson NL et al.: Autoimmune response to advanced glycosylation end-products of human LDL. J. Lipid Res. 44(3),487-493 (2003).
50. Alving CR, Swartz GM Jr: Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit. Rev. Immunol. 10(5), 441-453 (1991).
51. Horváth A, Füst G, Horváth I et al.: Anti-cholesterol antibodies (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA. Atherosclerosis 156(1), 185-192 (2001).
52. Veres A, Füst G, Smieja M et al.: Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation 106(22), 2775-2780 (2002).
53. Zhu J, Quyyumi AA, Rott D et al.: Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103(8), 1071-1075 (2001).
54. Proházka Z, Duba J, Horváth L et al.: Comparative study on antibodies to human and bacterial 60 kDa heat shock proteins in a large cohort of patients with coronary heart disease and healthy subjects. Eur. J. Clin. Invest. 31(4), 285-292 (2001).
55. Huittinen T, Leinonen M, Tenkanen L et al.: Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk. Arterioscler. Thromb. Vasc. Biol. 22(3), 431-437 (2002).
56. Perschinka H, Mayr M, Millonig G et al.: Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23(6), 1060-1065 (2003).
57. Marai I, Shechter M, Langevitz P et al.: Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease. Am. J. Cardiol. 101(8), 1094-1097 (2008).
58. Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E: Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin. Dev. Immunol. 2008, 723539 (2008).
59. Frostegard J, Ulfgren AK, Nyberg P et al.: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145(1), 33-43 (1999).
60. Szodoray P, Timar O, Veres K et al.: TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines - immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand. J. Immunol. 64(3), 336-344 (2006).
61. Pereira IA, Borba EF: The role of Inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med. Wkly 138(37-38), 534-539 (2008).
62. Park H, Li Z, Yang XO et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6(11), 1133-1141 (2005).
63. Bacci S, Pieri L, Buccoliero AM, Bonelli A, Taddei G, Romagnoli P: Smooth muscle cells, dendritic cells and mast cells are sources of TNFα and nitric oxide in human carotid artery atherosclerosis. Thromb. Res. 122(5), 657-667 (2008).
64. Kaartinen M, Penttilä A, Kovanen PT: Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90(4), 1669-1678 (1994).
65. Businaro R, Digregorio M, Riganò R et al.: Morphological analysis of cell subpopulations within carotid atherosclerotic plaques. Ital. J. Anat. Embryol. 110(2 Suppl. 1), 109-115 (2005).
66. Lindstedt KA, Mäyränpää MI, Kovanen PT: Mast cells in vulnerable atherosclerotic plaques - a view to a kill. J. Cell. Mol. Med. 11(4), 739-758 (2007).
67. Libby P, Shi GP: Mast cells as mediators and modulators of atherogenesis. Circulation 115 (19), 2471-2473 (2007).
68. Heikkilä HM, Lätti S, Leskinen MJ, Hakala JK, Kovanen PT, Lindstedt KA: Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-α. Arterioscler. Thromb. Vasc. Biol. 28(2),309-314 (2008).
69. Mangge H, Hubmann H, Pilz S, Schauenstein K, Renner W, März W: Beyond cholesterol - inflammatory cytokines, the key mediators in atherosclerosis. Clin. Chem. Lab. Med. 42(5), 467-474 (2004).
70. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 101(18), 2149-2153 (2000).
71. Volpato S, Guralnik JM, Ferrucci L et al.: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 103(7), 947-953 (2001).
72. Kleemann R, Zadelaar S, Kooistra T: Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 79(3), 360-376 (2008).
73. Del Porto F, Laganà B, Nofroni I, Tinti F, Mitterhofer AP, D'Amelio R: Effects of tumour necrosis factor α blockade on lipid profile in active rheumatoid arthritis. Rheumatology (Oxford) 46(10), 1626-1627 (2007).
74. Hürlimann D, Forster A, Noll G et al.: Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106(17), 2184-2187 (2002).
75. Dahlqvist SR, Engstrand S, Berglin E, Johnson O: Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand. J. Rheumatol. 35(2), 107-111 (2006).
76. Szekanecz Z: Pro-inflammatory cytokines in atherosclerosis. Isr. Med. Assoc. J. 10(7), 529-530 (2008).
77. Shoenfeld Y, Gerli R, Doria A et al.: Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21), 3337-3347 (2005).
78. Sherer Y, Shoenfeld Y: Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2(2), 99-106 (2006).
79. Szekanecz Z, Kerekes G, Dér H et al.: Accelerated atherosclerosis in rheumatoid arthritis. Ann. NY Acad. Sci. 1108, 349-358 (2007).
80. Giles JT, Post W, Blumenthal RS, Bathon JM: Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2(6), 320-329 (2006).
81. Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y: Cardiac manifestations in antiphospholipid syndrome. Autoimmun. Rev. 6(6), 379-386 (2007).
82. Dér H, Kerekes G, Veres K et al.: Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16(7), 497-503 (2007).
83. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y: Atherosclerosis and antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 25(1), 79-87 (2003).
84. Sherer Y, Gerli R, Gilburd B et al.: Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 16(4), 259-264 (2007).
85. van Doornum S, McColl G, Wicks IP: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46(4), 862-873 (2002).
86. Solomon DH, Karlson EW, Rimm EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9), 1303-1307 (2003).
87. Szücs G, Timár O, Szekanecz Z et al.: Endothelial dysfunction precedes atherosclerosis in systemic sclerosis - relevance for prevention of vascular complications. Rheumatology 46(5), 759-762 (2007).
88. Andersen GN, Caidahl K, Kazzam E et al.: Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecule E selectin, intercellular adhesion molecule 1 and vascular adhesion molecule 1. Arthritis Rheum. 43(5), 1085-1093 (2000).
89. Frostegård J: Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol. 25(9), 1776-1785 (2005).
90. Matsuura E, Kobayashi K, Matsunami Y, Lopez LR: The immunology of atherothrombosis in the antiphospholipid syndrome: antigen presentation and lipid intracellular accumulation. Autoimmun. Rev. DOI:10.1016/ j.autrev.2008.12.018 (2009) (Epub ahead of print).
91. Libby P: Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. J. Med. 121(10 Suppl. 1), S21-S31 (2008).
92. Beltowski J: Leptin and atherosclerosis. Atherosclerosis 189(1), 47-60 (2006).
93. Bełtowski J, Jamroz-Wiśniewska A, Widomska S: Adiponectin and its role in cardiovascular diseases. Cardiovas. Hematol. Disord. Drug Targets 8(1), 7-46 (2008).
94. Fantuzzi G, Mazzone T: Adipose tissue and atherosclerosis: exploring the connection. Arterioscler. Thromb. Vasc. Biol. 27(5), 996-1003 (2007).
95. Wannamethee SG, Tchernova J, Whincup P et al.: Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 191(2), 418-426 (2007).
96. Patel SB, Reams GP, Spear RM et al.: Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr. Hypertens. Rep. 10(2), 131-137 (2008).
97. Bouloumie A, Marumo T, Lafontan M et al.: Leptin induces oxidative stress in human endothelial cells. FASEB J. 13(10), 1231-1238 (1999).
98. Curat CA, Miranville A, Sengenès C et al.: From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53(5), 1285-1292 (2004).
99. Dubey L, Hersong Z: Role of leptin in atherogenesis. Exp. Clin. Cardiol. 11(4), 269-275 (2006).
100. Bobbert T, Rochlitz H, Wegewitz U et al.: Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54(9), 2712-2719 (2005).
101. Tomizawa A, Hattori Y, Kasai K, Nakano Y: Adiponectin induces NF-κB activation that leads to suppression of cytokine-induced NF-κB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab. Vasc. Dis. Res. 5(2),123-127 (2008).
102. Rizza S, Clementi F, Porzio O et al.: Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD. Nutr. Metab. Cardiovasc. Dis. 19(1), 54-60 (2009).
103. Kawanami D, Maemura K, Takeda N et al.: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem. Biophys. Res. Commun. 314(2), 415-419 (2004).
104. Xu W, Yu L, Zhou W, Luo M: Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem. Biophys. Res. Commun. 351(2), 376-382 (2006).
105. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ: Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem. Biophys. Res. Commun. 334(4), 1092-1101 (2005).
106. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7), 932-939 (2005).
107. Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA: High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J. Clin. Endocrinol. Metab. 91(7), 2755-2760 (2006).
108. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256(20), 2835-2838 (1986).
109. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58(3), 342-374 (2006).
110. Khovidhunkit W, Kim MS, Memon RA et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45(7), 1169-1196 (2004).
111. Esteve E, Ricart W, Fernández-Real JM: Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. 24(1), 16-31 (2005).
112. Van Lenten BJ, Hama SY, de Beer FC et al.: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96(6), 2758-2767 (1995).
113. Hoffman JS, Benditt EP: Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J. Clin. Invest. 71(4),926-934 (1983).
114. Tam SP, Flexman A, Hulme J, Kisilevsky R: Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A. J. Lipid Res. 43(9), 1410-1420 (2002).
115. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA: A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45(11), 1967-1974 (2004).
116. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Ravandi A, Kuksis A: Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res. 41(7), 1035-1047 (2000).
117. Lamarche B, Rashid S, Lewis GF: HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta. 286(1-2), 145-161 (1999).
118. Shah PK: Link between infection and atherosclerosis: who are the culprits: viruses, bacteria, both, or neither? Circulation 103(1), 5-6 (2001).
119. Zhang S, Guo Y, Ma Y, Teng Y: Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chin. Med. J. (Engl.) 121(10), 946-951 (2008).
120. Coombes BK, Mahony JB: Chlamydia pneumoniae infection of endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect. Immun. 67(6), 2909-2915 (1999).
121. Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI: Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect. 1(6), 409-418 (1999).
122. Andraws R, Berger JS, Brown DL: Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 293(21), 2641-2647 (2005).
123. Joensen JB, Juul S, Henneberg E, Thomsen G, Ostergaard L, Lindholt JS: Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 196(2), 937-942 (2008).
124. Vahdat K, Jafari SM, Nabipour I, Pazoki R: Concurrent increased high sensitivity C-reactive protein and chronic infections are associated with electrocardiogram-defined coronary artery disease: a population-based study. Indian J. Med. Sci. 61(3), 135-143 (2007).
125. Jonasson L: The possible link between infections and atherosclerosis. Indian J. Med. Sci. 61(3), 124-126 (2007).
126. + T cell subsets in patients with coronary artery disease: relation to cytomegalovirus infection. J. Intern. Med. 254(5), 472-478 (2003).
127. Baumert J, Schmidt KH, Eitner A, Straube E, Rödel J: Host cell cytokines induced by Chlamydia pneumoniae decrease the expression of interstitial collagens and fibronectin in fibroblasts. Infect. Immun. 77(2), 867-876 (2008).
128. Strååt K, de Klark R, Gredmark S, Eriksson P, Söderberg-Nauclér C: Infection by human cytomegalovirus alters the MMP-9/TIMP-1 balance in human macrophages. J. Virol. 83(2), 830-835 (2008).
129. Takeda K, Akira S: Toll-like receptors in innate immunity. Int. Immunol. 17(1), 1-14 (2005).
130. Erridge C: The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc. Med. 18(2), 52-56 (2008).
131. Wagner H: Endogenous TLR ligands and autoimmunity. Adv. Immunol. 91, 159-173 (2006).
132. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL: Oxidized low density lipoprotein and innate immune receptors. Curr. Opin. Lipidol. 14(5), 437-445 (2003).
133. Erridge C, Spickett CM: Oxidised phospholipid regulation of Toll-like receptor signalling. Redox Rep. 12(1),76-80 (2007).
134. Netea MG, Kullberg BJ, Demacker PN et al.: Native LDL potentiate TNF α and IL-8 production by human mononuclear cells. J. Lipid Res. 43(7), 1065-1071 (2002).
135. Gershov D, Kim S, Brot N, Elkon KB: C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med. 192(9), 1353-1364 (2000).
136. de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y: C-Reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol. Port. 32(4), 317-322 (2007).
137. Potempa LA, Siegel JN, Fiedel BA, Potempa RT, Gewurz H: Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol. Immunol. 24(5), 531-541 (1987).
138. Khreiss T, József L, Potempa LA, Filep JG: Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109(16), 2016-2022 (2004).
139. Liuzzo G, Biasucci LM, Gallimore JR et al.: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. Med. 331(7), 417-424 (1994).
140. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. Med. 336(14), 973-979 (1997).
141. Paul A, Ko KW, Li L et al.: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109(5), 647-655 (2004).
142. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102(18), 2165-2168 (2000).
143. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82(2), 513-520 (1993).
144. Torzewski M, Rist C, Mortensen RF et al.: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20(9), 2094-2099 (2000).
145. Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103(9), 1194-1197 (2001).
146. Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. Med. 359(21), 2195-2207 (2008).
147. Balla J, Magyar T, Bereczki D et al.: Serum levels of platelet released CD40 ligand are increased in early onset occlusive carotid artery disease. Dis. Markers 22(3),133-140 (2006).
148. Li G, Sanders JM, Bevard MH et al.: CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am. J. Pathol. 172(4), 1141-1152 (2008).
149. Everett BM, Bansal S, Rifai N, Buring JE, Ridker PM: Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 202(1), 282-288 (2008).
150. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343(6257), 425-430 (1990).
151. Martin G, Duez H, Blanquart C et al.: Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 107(11), 1423-1432 (2001).
152. Arnaud C, Burger F, Steffens S et al.: Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 25(6), 1231-1236 (2005).
153. Rezaie-Majd A, Maca T, Bucek RA et al.: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22(7), 1194-1199 (2002).
154. Waehre T, Damås JK, Gullestad L et al.: Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J. Am. Coll. Cardiol. 41(9), 1460-1467 (2003).
155. Veillard NR, Braunersreuther V, Arnaud C et al.: Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188(1), 51-58 (2006).
156. Youssef S, Stüve O, Patarroyo JC et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911), 78-84 (2002).
157. Shimada K, Miyauchi K, Daida H: Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation 109(18), E213-E214 (2004).
158. Arnaud C, Braunersreuther V, Mach F: Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc. Med. 15(6), 202-206 (2005).
159. Abeles AM, Pillinger MH: Statins as anti-inflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum. 54(2),393-407 (2006).
160. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat. Med. 6(12), 1399-1402 (2000).
161. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7(6), 687-692 (2001).
162. Mulhaupt F, Matter CM, Kwak BR et al.: Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 59(3), 755-766 (2003).
163. Krysiak R, Okopień B: Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol. Rep. 60(4), 514-523 (2008).
164. Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Praticò D: Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106(10), 1282-1287 (2002).
165. Redondo S, Santos-Gallego CG, Ganado P et al.: Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β. Circulation 107(4),626-629 (2003).
166. Tiran A, Gruber HJ, Graier WF, Wagner AH, Van Leeuwen EB, Tiran B: Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-κB activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22(7), 1075-1080 (2002).
167. Modica A, Karlsson F, Mooe T: Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J. Thromb. Haemost. 5(3), 507-511 (2007).